These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 12899533

  • 1. A low-calcemic vitamin D analog (Ro 25-4020) inhibits the growth of LNCaP human prostate cancer cells with increased potency by producing an active 24-oxo metabolite (Ro 29-9970).
    Swami S, Zhao XY, Sarabia S, Siu-Caldera ML, Uskokovic M, Reddy SG, Feldman D.
    Recent Results Cancer Res; 2003; 164():349-52. PubMed ID: 12899533
    [Abstract] [Full Text] [Related]

  • 2. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 3. 1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells.
    Siu-Caldera ML, Clark JW, Santos-Moore A, Peleg S, Liu YY, Uskoković MR, Sharma S, Reddy GS.
    J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):405-12. PubMed ID: 9010346
    [Abstract] [Full Text] [Related]

  • 4. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
    Zhao XY, Eccleshall TR, Krishnan AV, Gross C, Feldman D.
    Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
    [Abstract] [Full Text] [Related]

  • 5. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
    Verlinden L, Verstuyf A, Quack M, Van Camp M, Van Etten E, De Clercq P, Vandewalle M, Carlberg C, Bouillon R.
    J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
    [Abstract] [Full Text] [Related]

  • 6. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
    Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP.
    Cancer Res; 1999 Aug 15; 59(16):4023-9. PubMed ID: 10463602
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.
    Recent Results Cancer Res; 2003 Aug 15; 164():273-88. PubMed ID: 12899529
    [Abstract] [Full Text] [Related]

  • 8. Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor.
    Okano T, Nakagawa K, Tsugawa N, Ozono K, Kubodera N, Osawa A, Terada M, Mikami K.
    Biol Pharm Bull; 1998 Dec 15; 21(12):1300-5. PubMed ID: 9881643
    [Abstract] [Full Text] [Related]

  • 9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Dec 15; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 10. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1993 May 15; 132(5):1952-60. PubMed ID: 7682937
    [Abstract] [Full Text] [Related]

  • 11. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY, Peehl DM, Navone NM, Feldman D.
    Endocrinology; 2000 Jul 15; 141(7):2548-56. PubMed ID: 10875257
    [Abstract] [Full Text] [Related]

  • 12. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 13. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 01; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 14. Potent vitamin D3 analogs: their abilities to enhance transactivation and to bind to the vitamin D3 response element.
    Imai Y, Pike JW, Koeffler HP.
    Leuk Res; 1995 Mar 01; 19(3):147-58. PubMed ID: 7700077
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and biological activities of 26-hydroxy-27-nor-derivatives of 1 alpha, 25-dihydroxyvitamin D3.
    Scheddin D, Mayer H, Wittmann S, Schönecker B, Gliesing S, Reichenbächer M.
    Steroids; 1996 Oct 01; 61(10):598-608. PubMed ID: 8910973
    [Abstract] [Full Text] [Related]

  • 16. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3370-5. PubMed ID: 9699668
    [Abstract] [Full Text] [Related]

  • 17. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
    Campbell MJ, Reddy GS, Koeffler HP.
    J Cell Biochem; 1997 Sep 01; 66(3):413-25. PubMed ID: 9257197
    [Abstract] [Full Text] [Related]

  • 18. Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity.
    Verlinden L, Verstuyf A, Verboven C, Eelen G, De Ranter C, Gao LJ, Chen YJ, Murad I, Choi M, Yamamoto K, Yamada S, Van Haver D, Vandewalle M, De Clercq PJ, Bouillon R.
    J Biol Chem; 2003 Sep 12; 278(37):35476-82. PubMed ID: 12829710
    [Abstract] [Full Text] [Related]

  • 19. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.
    Staal A, Van Wijnen AJ, Desai RK, Pols HA, Birkenhäger JC, Deluca HF, Denhardt DT, Stein JL, Van Leeuwen JP, Stein GS, Lian JB.
    Endocrinology; 1996 May 12; 137(5):2001-11. PubMed ID: 8612541
    [Abstract] [Full Text] [Related]

  • 20. Metabolism and Action of 25-Hydroxy-19-nor-Vitamin D₃ in Human Prostate Cells.
    Munetsuna E, Kittaka A, Chen TC, Sakaki T.
    Vitam Horm; 2016 May 12; 100():357-77. PubMed ID: 26827959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.